
Ascendis Pharma A/S ASND
$ 222.44
0.7%
Annual report 2025
added 03-14-2026
Ascendis Pharma A/S Operating Cash Flow 2011-2026 | ASND
Annual Operating Cash Flow Ascendis Pharma A/S
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -418 M | -272 M | -176 M | -139 M | -95.1 M | -60.2 M | -43.5 M | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -43.5 M | -418 M | -172 M |
Quarterly Operating Cash Flow Ascendis Pharma A/S
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -131 M | - | - | - | -81.6 M | - | - | - | -66.8 M | - | - | - | -60.9 M | - | - | - | -36.7 M | - | - | - | -21.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -21.2 M | -131 M | -66.3 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
156 M | $ 19.67 | 0.51 % | $ 919 M | ||
|
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | ||
|
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | ||
|
BioNTech SE
BNTX
|
890 M | $ 88.99 | 0.25 % | $ 27.2 B | ||
|
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
-22.3 M | - | 10.36 % | $ 9.8 M | ||
|
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | ||
|
Cabaletta Bio
CABA
|
-131 M | $ 2.85 | 2.52 % | $ 286 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | ||
|
Compugen Ltd.
CGEN
|
31.6 M | $ 2.1 | 1.94 % | $ 196 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
-64.5 M | $ 8.4 | 1.08 % | $ 112 M | ||
|
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | ||
|
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | ||
|
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-13 M | $ 1.09 | -9.17 % | $ 22.4 M | ||
|
Equillium
EQ
|
-22.7 M | $ 2.06 | - | $ 118 M | ||
|
Esperion Therapeutics
ESPR
|
-13.1 M | $ 2.78 | 0.54 % | $ 578 M | ||
|
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | ||
|
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.35 | 1.13 % | $ 344 M | ||
|
Halozyme Therapeutics
HALO
|
652 M | $ 63.86 | 0.98 % | $ 7.65 B | ||
|
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | ||
|
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B | ||
|
Harmony Biosciences Holdings
HRMY
|
348 M | $ 27.64 | 0.18 % | $ 1.59 B | ||
|
bluebird bio
BLUE
|
-235 M | - | - | $ 546 M | ||
|
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
-92.1 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
-75.6 M | - | - | $ 3.74 B | ||
|
Immatics N.V.
IMTX
|
-81.8 M | $ 9.86 | 1.18 % | $ 620 M | ||
|
Ironwood Pharmaceuticals
IRWD
|
104 M | $ 3.23 | 1.25 % | $ 514 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | ||
|
Avid Bioservices
CDMO
|
11 M | - | - | $ 789 M | ||
|
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | ||
|
Johnson & Johnson
JNJ
|
24.5 B | $ 239.97 | 0.02 % | $ 578 B | ||
|
Bellerophon Therapeutics
BLPH
|
-17.8 M | - | -74.18 % | $ 955 K | ||
|
Karyopharm Therapeutics
KPTI
|
-127 M | $ 5.3 | 1.73 % | $ 646 K | ||
|
Kazia Therapeutics Limited
KZIA
|
-22.8 M | $ 7.3 | - | $ 967 M |